Catalent Confirms the Appointment of Two Senior Healthcare Executives to Its Board of Directors
15 August 2014 - 2:18AM
Business Wire
Catalent, Inc. (NYSE:CTLT), the global leader in drug
development solutions and advanced delivery technologies for
pharmaceutical, biologic, and consumer health products, today
announced that it has appointed Jack Stahl and Rolf Classon to its
Board of Directors.
Mr. Jack Stahl was President and Chief Executive Officer of
Revlon, Inc. between 2002 and 2006. Previously, he acted as
President and Chief Operating Officer of The Coca-Cola Company from
2000 to 2001. Mr. Stahl also serves on the Boards of Coty, Inc.,
Delhaize Group, and the U.S. Board of Advisors of CVC Capital.
Additionally, Mr. Stahl formerly served on the Boards of
Schering-Plough Corporation and Dr Pepper Snapple Group. He holds a
Bachelor’s degree in Economics from Emory University and a Master’s
degree from the Wharton School of Business at the University of
Pennsylvania.
Mr. Rolf Classon was Chairman of the Executive Committee at
Bayer HealthCare AG, a subsidiary of Bayer AG, from October 2002
until his retirement in July 2004. He served as President of Bayer
Diagnostics from 1995 to 2002 and as Executive Vice President from
1991 to 1995. Prior to 1991, Mr. Classon held various management
positions with Pharmacia Corporation. Mr. Classon currently serves
as Chairman of the Boards of Auxilium Pharmaceuticals, Inc.,
Hill-Rom Corporation, and Tecan Group Ltd., and he serves on the
Board of Fresenius Medical Care. Mr. Classon served as Vice
Chairman of Auxilium Pharmaceuticals, Inc. from March 2005 to April
2005, and he was interim Chief Executive Officer of Hill-Rom
Corporation from May 2005 until March 2006. Mr. Classon also served
as a Director on the Boards of Millipore Corporation, Prometheus
Laboratories Inc., and Enzon Pharmaceuticals, Inc. Mr. Classon
received his Chemical Engineering Certificate from the Gothenburg
School of Engineering and a Business degree from the Gothenburg
University.
Messrs. Stahl and Classon have also joined Catalent’s Audit
Committee, with Mr. Stahl serving as Chair.
“We welcome both Jack and Rolf to our Board,” commented John
Chiminski, President and CEO, Catalent, Inc. “Both are senior
healthcare executives, with a wealth of knowledge and experience
within the sector. We will look to draw upon their expertise as we
embark on the next, exciting stage of our Company’s history.”
About Catalent, Inc.
Catalent, Inc. is the leading global provider of advanced
delivery technologies and development solutions for drugs,
biologics and consumer health products. With over 80 years serving
the industry, Catalent has proven expertise in bringing more
customer products to market faster, enhancing product performance
and ensuring reliable clinical and commercial product supply.
Catalent employs approximately 8,000 people, including over 1,000
scientists, at nearly 30 facilities across 5 continents. Catalent
is headquartered in Somerset, N.J. For more information, visit
www.catalent.com
Forward Looking Statements
This press release contains both historical and forward-looking
statements. All statements other than statements of historical fact
are, or may be deemed to be, forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended.
These forward-looking statements generally can be identified by the
use of statements that include phrases such as “believe,” “expect,”
“anticipate”, “intend”, “estimate”, “plan”, “project”, “foresee”,
“likely”, “may”, “will”, “would” or other words or phrases with
similar meanings. Similarly, statements that describe our
objectives, plans or goals are, or may be, forward-looking
statements. These statements are based on current expectations of
future events. If underlying assumptions prove inaccurate or
unknown risks or uncertainties materialize, actual results could
vary materially from Catalent, Inc.’s expectations and projections.
Some of the factors that could cause actual results to differ
include, but are not limited to, the following: general industry
conditions and competition; product or other liability risk
inherent in the design, development, manufacture and marketing of
our offerings; inability to enhance our existing or introduce new
technology or services in a timely manner; economic conditions,
such as interest rate and currency exchange rate fluctuations;
technological advances and patents attained by competitors; and our
substantial debt and debt service requirements that restrict our
operating and financial flexibility and impose significant interest
and financial costs. For a more detailed discussion of these and
other factors, see the information under the caption “Risk Factors”
in our Prospectus dated July 30, 2014 filed with the Securities and
Exchange Commission. All forward-looking statements speak only as
of the date of this release or as of the date they are made, and
Catalent, Inc. does not undertake to update any forward-looking
statements as a result of new information or future events or
developments unless required by law.
More products. Better treatments. Reliably supplied.™
Media:Catalent, Inc.Chris Halling, +44 (0) 7580
041073chris.halling@catalent.comorRichard Kerns, +44 (0) 7974
579202richard@nepr.euorInvestors:Bertner Advisors, LLCMonique
Kosse, 860-940-0352Monique.Kosse@BertnerAdvisors.com
Catalent (NYSE:CTLT)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Catalent (NYSE:CTLT)
Historical Stock Chart
Von Jul 2023 bis Jul 2024